Prothena (NASDAQ:PRTA) is set to post its quarterly earnings results after the market closes on Tuesday, November 6th. Analysts expect Prothena to post earnings of ($1.05) per share for the quarter.
Prothena (NASDAQ:PRTA) last posted its quarterly earnings data on Tuesday, August 7th. The biotechnology company reported ($0.98) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.13) by $0.15. The company had revenue of $0.28 million for the quarter, compared to analyst estimates of $0.22 million. Prothena had a negative net margin of 21,884.38% and a negative return on equity of 46.42%. On average, analysts expect Prothena to post $-4 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
PRTA opened at $13.36 on Friday. The company has a market cap of $532.22 million, a PE ratio of -3.28 and a beta of 2.63. Prothena has a 52-week low of $10.43 and a 52-week high of $62.99.
A number of analysts have recently issued reports on PRTA shares. Cantor Fitzgerald reiterated a “buy” rating and set a $18.00 price objective on shares of Prothena in a research note on Wednesday, August 8th. BidaskClub upgraded shares of Prothena from a “hold” rating to a “buy” rating in a research note on Wednesday, August 15th. Zacks Investment Research upgraded shares of Prothena from a “sell” rating to a “hold” rating in a research note on Friday, August 10th. Finally, ValuEngine upgraded shares of Prothena from a “strong sell” rating to a “sell” rating in a research note on Tuesday, October 2nd. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating and three have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $36.67.
An institutional investor recently raised its position in Prothena stock. Bank of New York Mellon Corp increased its stake in Prothena Co. PLC (NASDAQ:PRTA) by 4.9% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 188,095 shares of the biotechnology company’s stock after buying an additional 8,842 shares during the period. Bank of New York Mellon Corp owned about 0.47% of Prothena worth $2,742,000 at the end of the most recent reporting period.
Prothena Company Profile
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on the discovery, development, and commercialization of novel immunotherapies for the treatment of diseases in the neuroscience and orphan categories. The company is developing antibody-based product candidates that include NEOD001, a monoclonal antibody that is in Phase III and Phase IIb clinical trials for the treatment of AL amyloidosis; PRX002/RG7935 that is in Phase II clinical trial for treating Parkinson's disease and other related synucleinopathies; and PRX004, a monoclonal antibody that is under preclinical development for the treatment of ATTR Amyloidosis.
Further Reading: How to Invest in the Dividend Aristocrat Index
Receive News & Ratings for Prothena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena and related companies with MarketBeat.com's FREE daily email newsletter.